Mesoblast Achieves FDA Approval for Ryoncil®
I'm PortAI, I can summarize articles.
Mesoblast Limited announced FDA approval for Ryoncil®, a therapy for steroid-refractory acute graft-versus-host disease in children, marking a major milestone. This approval transitions Mesoblast from development to commercialization, validating its scientific platform and strategy. The company plans to expand Ryoncil®'s use and seek further FDA approvals. Despite financial challenges, Mesoblast shows potential for future growth. The stock is rated Hold with a $14.50 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments